Harrow Raises $50M via Senior Notes as Ophthalmic Firm Funds Growth

Harrow ($HROW), a specialized ophthalmic disease management solutions provider, announced the pricing of a $50 million private offering of 8.625% senior unsecured notes due 2030, signaling the company's confidence in its growth trajectory while securing capital for near-term initiatives. The offering represents an expansion of the company's existing debt facility and is expected to close on March 27, 2026, with the firm planning to deploy proceeds toward new product launches, product development, and strategic business development opportunities.

Offering Details and Capital Structure

The newly priced notes will be issued as additional notes under the same indenture as $250 million in senior unsecured notes issued in September 2025, creating a combined debt issuance of $300 million in the same series. This structure demonstrates Harrow's ability to access capital markets efficiently by expanding an existing facility rather than establishing a new debt instrument.

Key offering metrics:

• Principal amount: $50 million
• Interest rate: 8.625%
• Maturity date: 2030
• Expected closing date: March 27, 2026
• Use of proceeds: General corporate purposes including product launches and strategic development
• Total outstanding notes in this series: $300 million

The 8.625% coupon rate reflects market conditions and the company's credit profile at the time of pricing. With a four-year maturity window from the March 2026 closing date, the debt structure provides Harrow with adequate time to generate returns from the capital deployment before principal repayment obligations come due.

Market Context and Industry Backdrop

The ophthalmic disease management sector has experienced consolidation and investment activity as healthcare providers seek specialized solutions for eye care and disease management. Harrow's ability to access the debt capital markets with a meaningful $50 million facility demonstrates investor appetite for the company's business model and growth prospects despite broader market volatility.

The pharmaceutical and medical device sectors have seen increased capital raising activity as companies pursue innovation in therapeutic areas with aging demographics driving demand. The ophthalmic space, in particular, benefits from:

• Aging population demographics driving increased prevalence of age-related eye diseases
• Rising healthcare spending on specialized disease management solutions
• Consolidation trends favoring integrated care providers
• Reimbursement improvements for advanced ophthalmic treatments

By securing $50 million in additional capital, Harrow positions itself to accelerate product development and launch initiatives that could strengthen its competitive positioning within the ophthalmic solutions market. The company's recent successful offering of $250 million in notes in September 2025 followed by the current $50 million expansion suggests strong investor confidence in management's capital allocation plans and growth strategy.

Investor Implications and Capital Deployment

For Harrow shareholders, this capital raise presents both opportunities and considerations. The company has clearly articulated its use of proceeds—new product launches, product development, and strategic business development opportunities—which should translate into revenue growth and market share expansion over the multi-year investment horizon.

The 8.625% interest rate represents a meaningful cost of capital that the company must service from operations. For this financing to be accretive to shareholder value, the company's return on invested capital from product launches and strategic initiatives must exceed this borrowing cost. The four-year maturity window provides reasonable runway for such returns to materialize.

Key considerations for investors:

• Leverage position: Combined $300 million in senior unsecured notes represents significant debt obligations that will require careful management of cash flow and working capital
• Refinancing risk: As notes mature in 2030, market conditions may impact Harrow's ability to refinance or repay this debt
• Growth execution: The company's ability to successfully launch products and execute on strategic initiatives directly impacts whether this capital raise creates or destroys shareholder value
• Competitive positioning: The investment in product development should enhance Harrow's ability to compete in the specialized ophthalmic solutions market

The decision to tap debt markets rather than dilute existing shareholders through equity issuance suggests management confidence in the company's ability to service debt while generating returns. This capital structure choice may be viewed favorably by existing shareholders if execution on the stated use of proceeds materializes as expected.

Looking Ahead

Harrow's $50 million senior notes offering reflects a strategic inflection point for the ophthalmic disease management solutions provider. With $300 million in committed capital from the debt markets, the company has secured meaningful resources to execute its growth agenda. The critical variable for investors will be whether management successfully deploys this capital into products and strategic initiatives that drive revenue growth and EBITDA expansion sufficient to justify the 8.625% coupon rate and strengthen the company's long-term financial position. As the offering closes in late March 2026, investor attention will likely turn toward quarterly earnings results and management updates on product launch timelines and market penetration metrics.